MARC SINATRA’S BIOGUIDE BRIEF: BIOTA
October 17th 2010 22:44
Biotech Daily
Monday September 13, 2010
Daily news on ASX-listed biotechnology companies
Monday September 13, 2010
Daily news on ASX-listed biotechnology companies
subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
BIOTA, DAIICHI SANKYO & A NEW GENERATION ’FLU DRUG
Biota shareholders got some good news today when Biota announced that their Japanese partner, Daiichi Sankyo, had successfully gained regulatory approval to market their next generation ‘flu drug, Inavir in Japan. Biota will receive royalties on Inavir’s sales.
Both companies are now looking to licence the drug in the rest of the world.
Anti-flu drugs have historically sold well in Japan, but not in the rest of the world, except for stockpiling for pandemic ‘flu prevention.
It will be interesting to see what sort of response Biota and Daiichi Sankyo get while shopping Inavir around.
The general lesson from the swine flu outbreak seems to be that no matter what we do, we won’t be able to stop or control similar future outbreaks.
Consequently, interest is now focused on developing treatments for those who get life-threateningly sick from the ‘flu, not the general public.
Still, some company may be willing to take a punt that stockpiling will continue or that Inavir will work well enough to improve its take up in the US and EU to make it a successful product.
Only time will tell.
Biota climbed 15.5 cents or 17.4 percent to $1.045 with 5.4 million shares traded.
Marc Sinatra’s Bioguide
email: marc@biotechdaily.com.au
email: marc@biotechdaily.com.au
Biotech Daily editor David Langsam owns Biota shares.
subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 54 |
| Vote |
Add To: 
subscribe to this blog